Drug intelligence / Profile preview

Lockdown

Development stage: Unknown
Lead developer: Universität Konstanz

Overview

Lockdown: sourced facts only. name: "Here, we use high-throughput screening to identify Lockdown, a reversible and non-competitive PPM1F inhibitor." [PMID:35443151]; target: "Here, we use high-throughput screening to identify Lockdown, a reversible and non-competitive PPM1F inhibitor." [PMID:35443151]; developer: "Lehrstuhl Zellbiologie, Department of Biology, University of Konstanz, Maildrop 621, Universitätsstrasse 10, 78467 Konstanz, Germany; Konstanz Research School Chemical Biology, University of Konstanz, Universitätsstrasse 10, 78467 Konstanz, Germany." [PMID:35443151]

Targets

STP family (Serine/threonine phosphatase family)

Beyond the preview

Go deeper on Lockdown.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lockdown.